Repatha vs Leqvio
A side-by-side look at two cardiovascular medications advertised on TV. Informational only — not medical advice.
| US Repatha | US Leqvio | |
|---|---|---|
| Generic name | evolocumab | inclisiran |
| Drug class | PCSK9 Inhibitor (Biologic) | siRNA PCSK9-Lowering Therapy |
| Treats | High cholesterol, cardiovascular disease | High cholesterol, cardiovascular disease |
| Category | Cardiovascular | Cardiovascular |
| Manufacturer | Amgen | Novartis |
| Year approved | 2015 | 2021 |
| FDA warning | No boxed warning | No boxed warning |
| Est. TV ad spend | $120M | $90M |
| Common side effects | Injection site reactions, Allergic reactions, Back pain, Fatigue | Injection site reactions, Joint pain, Urinary tract infection, Shortness of breath |
Frequently asked questions
Is Repatha or Leqvio better?
Neither is universally "better." Repatha (evolocumab) and Leqvio (inclisiran) are both used for cardiovascular, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Repatha and Leqvio?
Repatha is a PCSK9 Inhibitor (Biologic) made by Amgen, while Leqvio is a siRNA PCSK9-Lowering Therapy made by Novartis. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Repatha has the larger estimated TV advertising budget of the two.